Inactive Instrument

Rain Oncology Inc.

Equities

RAIN

US75082Q1058

Biotechnology & Medical Research

Rain Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022

May 04, 2022 at 04:15 pm EDT

Rain Therapeutics Inc. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported net loss was USD 17.39 million compared to USD 6.8 million a year ago.

Latest news about Rain Oncology Inc.

Rain Oncology Acquisition by Pathos AI Completed	Jan. 26	MT
Rain Oncology Inc.(NasdaqGS:RAIN) dropped from NASDAQ Composite Index	Jan. 26	CI
Rain Oncology Inc.(NasdaqGS:RAIN) dropped from S&P TMI Index	Jan. 26	CI
Pathos AI, Inc. completed the acquisition of Rain Oncology Inc. on January 26, 2024.	Jan. 25	CI
Rain Oncology Agrees to be Acquired by Pathos AI	Dec. 14	MT
Rain Oncology Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Rain Oncology Insider Bought Shares Worth $279,030, According to a Recent SEC Filing	23-10-13	MT
Concentra Biosciences, LLC submits a non-binding proposal to acquire Rain Oncology Inc. from Tang Capital Partners, LP, managed by Tang Capital Management, LLC and others for $45.5 million.	23-10-12	CI
Citigroup Trims Rain Oncology's Price Target to $1 From 1.50, Keeps Neutral Rating	23-09-18	MT
Transcript : Rain Oncology Inc., Q2 2023 Earnings Call, Aug 10, 2023	23-08-10
Rain Oncology Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Rain Oncology Inc.(NasdaqGS:RAIN) added to Russell Small Cap Comp Value Index	23-06-23	CI
Rain Oncology Inc.(NasdaqGS:RAIN) added to Russell 3000 Index	23-06-23	CI
Rain Oncology Inc.(NasdaqGS:RAIN) added to Russell 3000E Index	23-06-23	CI
Rain Oncology Inc.(NasdaqGS:RAIN) added to Russell Small Cap Completeness Index	23-06-23	CI
Rain Oncology Inc.(NasdaqGS:RAIN) added to Russell 2500 Index	23-06-23	CI
Rain Oncology Inc.(NasdaqGS:RAIN) added to Russell 2000 Index	23-06-23	CI
Rain Oncology Inc.(NasdaqGS:RAIN) added to Russell 3000E Value Index	23-06-23	CI
Rain Oncology Inc.(NasdaqGS:RAIN) added to Russell 3000 Value Index	23-06-23	CI
Rain Oncology Inc.(NasdaqGS:RAIN) added to Russell 2000 Value Index	23-06-23	CI
Rain Oncology Inc.(NasdaqGS:RAIN) added to Russell 2000 Dynamic Index	23-06-23	CI
Rain Oncology Inc.(NasdaqGS:RAIN) added to Russell Microcap Growth Index	23-06-23	CI
Rain Oncology Inc.(NasdaqGS:RAIN) added to Russell 3000E Growth Index	23-06-23	CI
Rain Oncology Inc.(NasdaqGS:RAIN) added to Russell 2500 Growth Index	23-06-23	CI
Rain Oncology Inc.(NasdaqGS:RAIN) added to Russell 3000 Growth Index	23-06-23	CI

Chart Rain Oncology Inc.

Duration

Period

More charts

Company Profile

Rain Oncology Inc. is a late-stage precision oncology company. The Company is focused on developing therapies that target oncogenic drivers to genetically select patients. Its product candidate includes milademetan. Milademetan is an oral, small molecule inhibitor of the p53-mouse double minute 2 (p53-MDM2) complex that reactivates p53. The product candidate is being developed in patients with MDM2-dependent cancers. p53 acts as a regulator of various cellular processes. The activity of p53 is controlled and regulated by the inhibitory protein MDM2. MDM2 binds to p53, thereby inducing degradation and allowing normal cells to function properly. Milademetan, by binding MDM2 at the p53 interaction site, prevents the formation of the MDM2-p53 complex, allowing p53 reactivation and subsequent transcription of genes that trigger cancer cell cycle arrest or apoptosis and can be readily measured by increases in the pharmacodynamic marker MIC-1 (GDF15) in the blood.

Sector

Biotechnology & Medical Research

Related indices

Russell 2000

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+1.12%	42.59B
MODERNA, INC.	+6.77%	40.65B
LONZA GROUP AG	+47.75%	40.57B
CELLTRION, INC.	-11.96%	26.77B
ICON PUBLIC LIMITED COMPANY	+6.01%	24.81B
ALNYLAM PHARMACEUTICALS, INC.	-24.92%	18.17B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.63%	11.7B
MEDPACE HOLDINGS, INC.	+27.16%	12.05B
UNITED THERAPEUTICS CORPORATION	+7.30%	11.1B

Other Biotechnology & Medical Research